Ocugen Shares Surge Ahead of Critical Clinical Data Releases

Investors are piling into Ocugen, Inc., driving a significant rally in the biotech firm’s share price. The upward momentum is directly tied to a series of imminent clinical trial readouts, with market participants positioning themselves ahead of these potential catalysts. Since the start of the year, the stock has advanced approximately 10%, accompanied by a marked increase in trading activity.

The market’s focus is evident in the volume data. On peak days, trading volume has soared to around 6 million shares, substantially above the average of 3.9 million. This activity underscores a market actively taking positions in expectation of near-term developments. The equity has climbed 32.5% over the past 30 days and boasts gains Read more...